Navigation Links
Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
Date:4/3/2008

BALTIMORE, April 3, 2008 /PRNewswire/ -- Lentigen Corporation today announced an exclusive licensing agreement with Cambridge Enterprise, the organization responsible for licensing technologies from the University of Cambridge (U.K.), for a fundamental patent in the area of lentiviral vector technology. The technology was developed in the laboratory of Professor Andrew Lever at the University of Cambridge.

"The patent broadly claims fundamental compositions of HIV-based lentiviral vectors that are currently widely used in research and clinical studies," said Boro Dropulic, Ph.D., founder, president and chief scientific officer of Lentigen. He added "we are delighted to be working with Professor Lever in obtaining this patent license, and developing its application in biomedicine."

Following the acquisition of the Cell Genesys' lentiviral patent portfolio late last year by GBP Capital, the majority shareholder in Lentigen, this license further consolidates Lentigen's intellectual property position.

"Licensing this fundamental technology patent from the University of Cambridge extends our strong intellectual property position and is consistent with our goal of becoming a leader in lentiviral-vector based biomedicine. It further enables Lentigen to pursue development and commercialization of biomedical products and services, to the benefit of patients, healthcare providers and the research community," said Tim Ravenscroft, chief executive officer of Lentigen.

"Lentigen are the ideal partner for this piece of fundamental lentiviral vector technology. We are pleased to be working with a team committed to developing the technology for patient benefit," added Dr Andrew Walsh, technology manager for Cambridge Enterprise, University of Cambridge.

About Lentiviral Vectors

Lentiviral vectors (LV) are the most efficient vehicles for stable delivery of genes or gene silencing sequences (e.g. RNAi) into cells. Gene delivery is acco
'/>"/>

SOURCE Lentigen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
2. Lentigen to Move Headquarters and Manufacturing to Gaithersburg
3. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
4. VIRxSYS and Lentigen Announce Litigation Settlement
5. U.S. FDA Licenses DAPTACEL(R) Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series
6. Egenix Licenses Harvard Anti-Cancer Platform
7. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
8. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
9. Prometheus Licenses COLAL-PRED(R) From Alizyme
10. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
11. Syngenta Licenses Chromatin Gene Stacking Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 WriteResult, LLC – a ... been working with a team of researchers from Yale ... Community Farming Collaborative to provide electronic questionnaire data collection ... study, which started in May, aims to evaluate the ... weekly exposure to and participation in urban agriculture to ...
(Date:10/22/2014)... Rock Hill, SC (PRWEB) October 22, 2014 ... the expansion of its cardiovascular pharmacogenetics menu, which ... improved patient outcomes. With PCLS’s evidence-based results, ... individual needs and optimize their therapy, while minimizing ... , In the U.S., according to the FDA ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced next steps for its Oral Amphotericin B ... its in vitro work involving samples ... now plans to complete pre clinical studies and ... Phase 1A clinical trial, utilizing approximately $700,000 of ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
Breaking Biology Technology:myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... York are pioneering the development of electron microscopes which ... materials in new revolutionary ways., The team, headed by ... University,s Department of Physics has created electron beams with ... will open the way to many novel applications including ...
... Inc. announced today the publication of key results relating ... discovery for high-value G-protein-coupled receptor (GPCR) targets in ... of a Lipid G Protein-Coupled Receptor," was co-authored by ... Ph.D., and Raymond Stevens, Ph.D. Drs. Rosen and Stevens ...
... Pa., Feb. 16, 2012  BioDelivery Sciences International, Inc. (Nasdaq: ... Trademark Office (USPTO) has issued a Notice of Allowance ... granted, will extend the exclusivity of the BioErodible MucoAdhesive ... Buprenorphine/Naloxone from 2020 to 2027.  A ...
Cached Biology Technology:York researchers create 'tornados' inside electron microscopes 2Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science 2Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science 3Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science 4BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals 2BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals 3BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals 4BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals 5
(Date:10/18/2014)... 2014 Psychological stress and stress-related psychiatric disorders are ... but the molecular mechanisms underlying this relation ... to the development of targeted preventive strategies ... devastating diseases. This work is presented at ... Berlin., Now an international group of researchers ...
(Date:10/17/2014)... shown for the first time how bacteria can grow ... them the opportunity to get tremendous insights into bacteria ... also discovered the bacterial growth in chronic lung infections ... down by the immune cells. The researchers discovered the ... the bacteria, forcing the bacteria to switch to a ...
(Date:10/16/2014)... the bowel lining develops and, in the process, suggested ... The researchers produced evidence that stem cells are responsible ... feature of the bowel lining, and believe these stem ... finding as scientists are still divided on the stem ... Wee Tan and Professor Tony Burgess from the Walter ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2
... CORVALLIS, Ore. Fungi have significant potential for "horizontal" ... mechanisms that allow bacteria to evolve so quickly, become resistant ... to be published Thursday in the journal Nature , ... make-up of their genomes and become infectious to plants and ...
... like a mashup of monster movies, but palaeontologists have discovered ... a killing that took place 4 million years ago. ... by careful, forensic-style analysis of bite marks on an otherwise ... have reconstructed the events that led to the death of ...
... scientists have successfully used geometrically patterned surfaces to influence ... a departure from that of many stem-cell biologists, who ... controlling the fate of stem cells. "The cells ... it,s the shape alone that,s dictating whether they turn ...
Cached Biology News:Fungi can change quickly, pass along infectious ability 2Jaws -- 4 million B.C. 2